This company is engaged in the research and development, production and sales of pharmaceutical_products. It was_established in DATE. The company is headquartered in STATE_OR_PROVINCE, China.It is mainly active in the research and development and production of protein CRIMINAL_CHARGE and biological preparations. Relying on the group 's R&D and technical advantages, it has mastered core_technologies including microbial culture technology, protein drug purification and formulation technology, and biopharmaceutical upstream and downstream process technology.The companyâ___s anti-tumor drug R&D and production base project in CITY covers_an_area of NUMBER mu, with a construction area of approximately_NUMBER_square_meters in the ORDINAL phase.The new type NUMBER anti-cancer drug ADI - PEG20 being developed by this project, its main mechanism is to use the different metabolic requirements of normal cells and CAUSE_OF_DEATH cells to deprive CAUSE_OF_DEATH cells of key amino acids to block the growth of CAUSE_OF_DEATH cells. ADI - PEG20 is suitable_for the treatment of various arginine - dependent cancers, such_as CAUSE_OF_DEATH_CAUSE_OF_DEATH, interstitial CAUSE_OF_DEATH_CAUSE_OF_DEATH, blood CAUSE_OF_DEATH,_CAUSE_OF_DEATH, CAUSE_OF_DEATH_CAUSE_OF_DEATH, CAUSE_OF_DEATH_CAUSE_OF_DEATH, CAUSE_OF_DEATH, etc. The results of clinical_trials have shown that its curative effect is clear and its side effects are mild. Through a series of patent applications, ADI - PEG20 has obtained extensive patent protection worldwide. Among the anti-tumor CRIMINAL_CHARGE with the same mechanism, ADI - PEG20 has technological_innovation and entered the clinical research stage ORDINAL.